Pacira Biosciences Inc Stock Price, News & Analysis

Pacira BioSciences (Nasdaq: PCRX), a leader in non-opioid pain therapies, has granted inducement awards to nine new employees under its Amended and Restated 2014 Inducement Plan. The awards, approved by the People & Compensation Committee on September 3, 2025, include:

• Stock Options: Six employees received options to purchase 13,000 shares at $27.18 per share, with a 10-year term and four-year vesting schedule
• Restricted Stock Units (RSUs): Nine employees received 18,100 RSUs, vesting annually in four equal installments starting September 1, 2026

Pacira BioSciences (Nasdaq: PCRX) reported Q2 2025 financial results with total revenues of $181.1 million. Key product sales included EXPAREL at $142.9 million, ZILRETTA at $31.3 million, and iovera° at $5.6 million. The company reported a net loss of $4.8 million ($0.11 per share) and adjusted EBITDA of $54.3 million.

Notable developments include surpassing 50% enrollment in the Phase 2 ASCEND study for PCRX-201, securing a new $300 million revolving credit facility, and entering a strategic collaboration with Johnson & Johnson MedTech. The company also received a $28.3 million favorable court ruling payment and strengthened its patent portfolio. Pacira updated its 2025 guidance, narrowing total revenue to $730-750 million and increasing non-GAAP gross margin to 78-80%.

The company repurchased 2.0 million shares at an average price of $25.59 per share, totaling $50.0 million.

Pacira BioSciences (NASDAQ: PCRX), a leader in non-opioid pain therapies, will release its second quarter 2025 financial results after U.S. markets close on Tuesday, August 5, 2025.

The company will host a conference call and webcast at 4:30 p.m. ET the same day. Participants can pre-register for the Q&A session via telephone, while the webcast will be accessible through the "Events" page on Pacira's investor website. A replay will be available for approximately two weeks following the call.

Pacira BioSciences (NASDAQ: PCRX) has announced a strategic collaboration with Johnson & Johnson MedTech to expand the market reach of ZILRETTA, their extended-release treatment for osteoarthritis knee pain. The partnership aims to leverage J&J's specialized early intervention sales force to co-promote the treatment.

The collaboration aligns with Pacira's 5x30 strategy and is expected to significantly expand access across the 7 million intra-articular knee injections administered annually in the U.S. The partnership will extend ZILRETTA's reach beyond orthopedic practices into sports medicine, pain management, and rheumatology specialties.

Pacira BioSciences (Nasdaq: PCRX), a leader in non-opioid pain therapies, announced inducement grants to seven new employees on July 2, 2025. The awards include stock options for 3,500 shares to one employee and restricted stock units (RSUs) for 12,300 shares to seven employees.

The stock options have a 10-year term with a four-year vesting schedule, starting at 25% after the first year, followed by quarterly installments. The options' exercise price is set at $23.21 per share. The RSUs vest annually in four equal installments beginning July 1, 2026. All awards require continued employment with Pacira.

Pacira BioSciences (NASDAQ: PCRX) premiered a new film at BIO 2025 titled 'The Next Frontier: Mark & Leah's Story,' produced by BBC StoryWorks Commercial Productions. The film chronicles former tennis player Mark Allen's journey from opioid dependency following knee injuries to successful recovery through non-opioid pain management solutions. The story showcases how Mark, with support from his nurse wife Leah, transformed his life using alternative pain therapies, enabling him to open a tennis academy and enjoy time with his grandchildren. The film debuts amid concerning statistics, with CDC reporting 54,743 opioid-related deaths in 2024. Chronic pain affects 82 million Americans and costs the U.S. up to $635 billion annually, exceeding the combined costs of cancer and heart disease, highlighting the urgent need for innovative non-opioid pain management solutions.

Pacira BioSciences (NASDAQ: PCRX) announced promising three-year clinical data for PCRX-201, their investigational gene therapy for knee osteoarthritis. The Phase 1 trial involving 72 patients demonstrated that a single intra-articular injection of PCRX-201 provided sustained improvements in pain, stiffness, and function through 156 weeks. Key results from the corticosteroid-pretreated cohort showed 51-53% reduction in pain scores, 38-76% reduction in stiffness scores, and 26-28-point improvements in daily living function scores. The therapy was well-tolerated with no serious treatment-related adverse events. PCRX-201, which received FDA's RMAT designation in March 2024 and EMA's ATMP designation in May 2023, works by targeting chronic inflammation at the cellular level through its proprietary HCAd gene therapy vector platform. The company is currently conducting Phase 2 trials following these encouraging results.

Pacira BioSciences (PCRX) has granted inducement awards to 19 new employees on June 3, 2025, under its Amended and Restated 2014 Inducement Plan. The awards include stock options for 11 employees to purchase 26,700 shares and restricted stock units (RSUs) for 19 employees covering 41,600 shares. The stock options have a 10-year term with a four-year vesting schedule, starting at 25% after the first year and quarterly installments thereafter. The exercise price is set at $26.40 per share. The RSUs vest annually in four equal installments beginning June 1, 2026. All awards are contingent on continued employment and were approved by the People & Compensation Committee without stockholder approval.

Pacira BioSciences (NASDAQ: PCRX) has presented promising preliminary data for its gene therapy candidate PCRX-201 in treating knee osteoarthritis. The Phase 1 trial involving 72 participants demonstrated that pre-existing and treatment-induced anti-Ad5 neutralizing antibodies do not impact the therapy's safety or effectiveness. The study showed that PCRX-201, which uses a proprietary high-capacity adenovirus vector platform, improved pain, stiffness, and function across all tested doses. Notably, corticosteroid pretreatment helped reduce treatment-induced antibody titers and joint swelling. The therapy received RMAT designation from the FDA in March 2024 and ATMP designation from the EMA in May 2023. A Phase 2 study (ASCEND) is currently underway, targeting the 14 million patients suffering from knee osteoarthritis.